Absorption kinetics of insulin after subcutaneous administration

European Journal of Pharmaceutical Sciences

Volumn 36, Issue 1, 2009, Pages 78-90

  Søeborg, Tue ^a   Rasmussen, Christian Hove ^b   Mosekilde, Erik ^b   Colding Jørgensen, Morten ^c  

^a DANISH MEDICINES AGENCY   (Denmark)

^b TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^c NOVO NORDISK A S   (Denmark)

Author keywords

Crystal parameter effect; Dose size effect; Insulin absorption; Insulin concentration effect; NPH insulin; Soluble insulin

Indexed keywords

BOVINE INSULIN; HUMAN INSULIN; INSULIN; ISOPHANE INSULIN; PIG INSULIN;

ARTICLE; CONCENTRATION RESPONSE; CRYSTAL; DIABETES MELLITUS; DRUG ABSORPTION; DRUG DIFFUSION; DRUG DISTRIBUTION; EQUILIBRIUM CONSTANT; HUMAN; INSULIN BLOOD LEVEL; IONIC STRENGTH; MAXIMUM PLASMA CONCENTRATION; PH; PRIORITY JOURNAL; SKIN BLOOD FLOW; SKINFOLD THICKNESS; TEMPERATURE;

ADSORPTION; ANIMALS; CRYSTALLIZATION; DIFFUSION; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN;

EID: 58049217303     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2008.10.018     Document Type: Article

References (87)

1. The United States Pharmacopoeia, 2008. 31st ed. The United States Pharmacopeial Convention, Baltimore.
2. Balschmidt P., Hansen F., Dodson E.J., Dodson G.G., and Korber F. Structure of porcine insulin cocrystallized with clupeine Z. Acta Cryst. B47 (1991) 975-986
3. Banting F., Best C., Collip J., Campbell W., and Fletcher A. Pancreatic extracts in the treatment of diabetes mellitus: preliminary report. Can. Med. Assoc. J. 12 (1922) 141-146
4. Berger M., and Rodbard D. Computer simulation of plasma insulin and glucose dynamics after subcutaneous insulin injection. Diabetes Care 12 (1989) 725-735
5. Binder C. A theoretical model for the absorption of soluble insulin. In: Brunetti P. (Ed). Artificial Systems For Insulin Delivery (1983), Raven Press, New York 53-57
6. Binder C. Absorption of injected insulin. Acta. Pharmacol. Toxicol. 27 Suppl. 2 (1969) 5-84
7. Bocian W., Sitkowski J., Bednarek E., Tarnowska A., Kawecki R., and Kozerski L. Structure of human insulin monomer in water/acetonitrile solution. J. Biomol. NMR 40 (2008) 55-64
8. Brange J., Owens D.R., Kang S., and Volund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care 13 (1990) 923-954
9. Brange J., Ribel U., Hansen J.F., Dodson G., Hansen M.T., Havelund S., Melberg S.G., Norris F., Norris K., Snel L., Sorensen A.R., and Voigt H.O. Monomeric insulins obtained by protein engineering and their medical implications. Nature 333 (1988) 679-682
10. Brems D.N., Alter L.A., Beckage M.J., Chance R.E., DiMarchi R.D., Green L.K., Long H.B., Pekar A.H., Shields J.E., and Frank B.H. Altering the association properties of insulin by amino acid replacement. Protein Eng. 5 (1992) 527-533
11. Bulow J., Hansen M., and Madsen J. Variation in human subcutaneous adipose tissue blood flow. Acta. Physiol. Scand. 96 (1976) 30A-31A
12. Chandler C., Gryniewicz C.M., Pringle T., and Cunningham F. Insulin temperature and stability under simulated transit conditions. Am. J. Health Syst. Pharm. 65 (2008) 953-963
13. Chitta R.K., Rempel D.L., Grayson M.A., Remsen E.E., and Gross M.L. Application of SIMSTEX to oligomerization of insulin analogs and mutants. J. Am. Soc. Mass. Spectrom. 17 (2006) 1526-1534
14. Cobelli C., Mari A., Del P.S., De K.S., Nosadini R., and Jensen I. Reconstructing the rate of appearance of subcutaneous insulin by deconvolution. Am. J. Physiol. 253 (1987) E584-E590
15. Cochran E., Musso C., and Gorden P. The use of U-500 in patients with extreme insulin resistance. Diabetes Care 28 (2005) 1240-1244
16. Coffman F.D., and Dunn M.F. Insulin-metal ion interactions: the binding of divalent cations to insulin hexamers and tetramers and the assembly of insulin hexamers. Biochemistry 27 (1988) 6179-6187
17. 125I-labelled insulin. Br. J. Clin. Pharmacol. 27 (1989) 461-467
18. DeFelippis M.R., Chance R.E., and Frank B.H. Insulin self-association and the relationship to pharmacokinetics and pharmacodynamics. Ther. Drug Carrier Syst. 18 (2001) 201-264
19. Derewenda U., Derewenda Z., Dodson E.J., Dodson G.G., Reynolds C.D., Smith G.D., Sparks C., and Swenson D. Phenol stabilizes more helix in a new symmetrical zinc insulin hexamer. Nature 338 (1989) 594-596
20. Dodd S., Havel H., Kovach P., Lakshminarayan C., Redmon M., Sargeant C., Sullivan G., and Beals J.M. Reversible adsorption of soluble hexameric insulin onto the surface of insulin crystals cocrystallized with protamine: an electrostatic interaction. Pharm. Res. 12 (1995) 60-68
21. Fischer U., Freyse E.J., Jutzi E., Besch W., Raschke M., Hofer S., and Albrecht G. Absorption rates of subcutaneously injected insulin in the dog as calculated from the plasma insulin levels by means of a simple mathematical model. Diabetologia 24 (1983) 196-201
22. Florence A., and Attwood D. Physicochemical Principles of Pharmacy. 3rd ed. (1998), Macmillan Press Ltd., Ebbw Vale
23. Frank B.H., Pekar A.H., and Veros A. Insulin and proinsulin conformation in solution. Diabetes 21 (1972) 486-491
24. Goldman J., and Carpenter F.H. Zinc binding, circular dichroism, and equilibrium sedimentation studies on insulin (bovine) and several of its derivatives. Biochemistry 13 (1974) 4566-4574
25. Hagedorn H., Jensen B., Krarup N., and Wodstrup I. Protamine insulinate. JAMA 106 (1936) 177-180
26. Hansen J.F. The self-association of zinc-free human insulin and insulin analogue B13-glutamine. Biophys. Chem. 39 (1991) 107-110
27. Hansen R.N. Glucose Homeostasis. A Biosimulation Approach (2004), Technical University of Denmark, Copenhagen
28. Hassiepen U., Federwisch M., Mulders T., and Wollmer A. The lifetime of insulin hexamers. Biophys. J. 77 (1999) 1638-1654
29. Heine R., Bilo H., Fonk T., van der Veen E., and van der Meer J. Absorption kinetics and action profiles of mixtures of short- and intermediate-acting insulins. Diabetologia 27 (1984) 558-562
30. Heinemann L. Insulin pharmacology. In: Pickup J., and Williams G. (Eds). In Textbook of Diabetes (2003), Blackwell Science, Malden, MA, USA 42.1-42.15
31. Heinemann L., Weyer C., Rave K., Stiefelhagen O., Rauhaus M., and Heise T. Comparison of the time-action profiles of U40- and U100-regular human insulin and the rapid-acting insulin analogue B28 Asp. Exp. Clin. Endocrinol. Diabetes 105 (1997) 140-144
32. Hildebrandt P., Sejrsen P., Nielsen S., Birch K., and Sestoft L. Diffusion and polymerization determines the insulin absorption from subcutaneous tissue in diabetic patients. Scand. J. Clin. Lab. Invest. 45 (1985) 685-690
33. Hildebrandt P. Skinfold thickness, local subcutaneous blood flow and insulin absorption in diabetic patients. Acta. Physiol. Scand. Suppl. 603 (1991) 41-45
34. Hildebrandt P., and Birch K. Basal rate subcutaneous insulin infusion: absorption kinetics and relation to local blood flow. Diabet. Med. 5 (1988) 434-440
35. Hildebrandt P., Birch K., Sestoft L., and Nielsen S.L. Orthostatic changes in subcutaneous blood flow and insulin absorption. Diabetes Res. 2 (1985) 187-190
36. Hildebrandt P., Sestoft L., and Nielsen S.L. The absorption of subcutaneously injected short-acting soluble insulin influence of injection technique concentration. Diabetes Care 6 (1983) 459-462
37. Hoffmann J.A., Chance R.E., and Johnson M.G. Purification and analysis of the major components of chum salmon protamine contained in insulin formulations using high-performance liquid chromatography. Prot. Express. Purif. 1 (1990) 127-133
38. Holladay L.A., Ascoli M., and Puett D. Conformational stability and self-association of zinc-free bovine insulin at neutral pH. Biochim. Biophys. Acta 494 (1977) 245-254
39. Hübinger A., Weber W., Jung W., Wehmeyer K., and Gries F.A. The pharmacokinetics of two different concentrations of short-acting insulin, intermediate-acting insulin, and an insulin mixture following subcutaneous injection. Clin. Invest. 70 (1992) 621-626
40. Hvidt S. Insulin association in neutral solutions studied by light scattering. Biophys. Chem. 39 (1991) 205-213
41. Jeffrey P.D., and Coates J.H. An Equilibrium ultracentrifuge study of the self-association of bovine insulin. Biochemistry 5 (1966) 489-498
42. Jeffrey P.D., Milthorpe B.K., and Nichol L.W. Polymerization pattern of insulin at pH 7.0. Biochemistry 15 (1976) 4660-4665
43. Jørgensen K., Hansen A., and Buschard K. Five fold increase of insulin concentration delays the absorption of subcutaneously injected human insulin suspensions in pigs. Diabetes Res. Clin. Pract. 50 (2000) 161-167
44. Kadima W., Øgendal L., Bauer R., Kaarsholm N., Brodersen K., Hansen J.F., and Porting P. The influence of ionic strength and pH on the aggregation properties of zinc-free insulin studied by static and dynamic laser light scattering. Biopolymers 33 (1993) 1643-1657
45. Kang S., Brange J., Burch A., Volund A., and Owens D. Subcutaneous insulin absorption explained by insulin's physicochemical properties. Diabetes Care 14 (1991) 942-948
46. Kobayashi T., Sawano S., Itoh T., Kosaka K., Hirayama H., and Kasuya Y. The pharmacokinetics of insulin after continuous subcutaneous infusion or bolus subcutaneous injection in diabetic patients. Diabetes 32 (1983) 331-336
47. Kølendorf K., Aaby P., Westergaard S., and Deckert T. Absorption, effectiveness and side effects of highly purified porcine NPH-insulin preparations (Leo). Eur. J. Clin. Pharmacol. 14 (1978) 117-124
48. Kølendorf K., Bojsen J., and Deckert T. Absorption and miscibility of regular procine insulin after subcutaneous injection of insulin treated diabetic patients. Diabetes Care 6 (1983) 6-9
49. Koren R., and Hammes G.G. A kinetic study of protein-protein interactions. Biochemistry 15 (1976) 1165-1171
50. Kraegen E., and Chisholm D. Insulin responses to varying profiles of subcutaneous insulin infusion: kinetic modelling studies. Diabetologia 26 (1984) 208-213
51. Krayenbühl C., and Rosenberg T. Crystalline protamine insulin. Reports of the Steno Memorial Hospital and the Nordisk Insulinlaboratorium,vol. 1 (1946) 61-73
52. Kurtzhals P., and Ribel U. Action profile of cobalt(III)-insulin a novel principle of protraction of potential use for basal insulin delivery. Diabetes 44 (1995) 1381-1385
53. Lauritzen T., Binder C., and Faber O. Importance of insulin absorption, subcutaneous blood flow, and residual beta-cell function in insulin therapy. Acta. Paediatr. Scand. Suppl. 283 (1980) 81-85
54. Lauritzen T., Thorsteinsson B., Pramming S., Sørensen L., and Binder C. Subcutaneous absorption of U-40 and U-100 insulin. Horm. Metabol. Res. 16 (1984) 611-612
55. Lehmann E., Tarín C., Bondia J., Teufel E., and Deutsch T. Incorporating a generic model of subcutaneous insulin absorption into the AIDA v4 diabetes simulator. 1. A prospective collaborative development plan. J. Diabetes Sci. Technol. 1 (2007) 423-435
56. Lehmann E., Tarín C., Bondia J., Teufel E., and Deutsch T. Incorporating a generic model of subcutaneous insulin absorption into the AIDA v4 diabetes simulator. 2. Preliminary bench testing. J. Diabetes Sci. Technol. 1 (2007) 780-793
57. Li, J., Kuang, Y., 2007. Pharmacokinetic models of subcutaneous injection of insulin analogues for type 1 diabetes. http://math.la.asu.edu/∼kuang/paper/JLi07.pdf. Accessed 24 June 2008.
58. Makroglou A., Li J., and Kuang Y. Mathematical models and software tools for the glucose-insulin regulatory system and diabetes: an overview. Appl. Numer. Math. 56 (2006) 559-573
59. Mark A.E., and Jeffrey P.D. The self-association of zinc-free bovine insulin four model patterns and their significance. Biol. Chem. Hoppe Seyler 371 (1990) 1165-1174
60. Mark A.E., Nichol L.W., and Jeffrey P.D. Single model based on interactions in the crystal that describes the association pattern in solution at pH 2, 7 and 10. Biophys. Chem. 27 (1987) 103-117
61. Massey E.H., and Anderson J.H. What were those crystals? The dissolution and disintegration of insulin. JAMA 259 (1988) 1811-1812
62. Mosekilde E., Jensen K., Binder C., Pramming S., and Thorsteinsson B. Modeling absorption kinetics of subcutaneously injected soluble insulin. J. Pharmacokin. Biopharm. 17 (1989) 67-87
63. Mosekilde E., Sosnovtseva O., and Holstein-Rathlou N.-H. Mechanism-based modeling of complex biomedical systems. Basic Clin. Pharmacol. Toxicol. 96 (2005) 212-224
64. Nettleton E., Tito P., Sunde M., Bouchard M., Dobson C., and Robinson C. Characterization of the oligomeric states of insulin in self-assembly and amyloid fibril formation by mass spectrometry. Biophys. J. 79 (2000) 1053-1065
65. Norrman M., Hubálek F., and Schluckebier G. Structural characterization of insulin NPH formulations. Eur. J. Pharm. Sci. 30 (2007) 414-423
66. Nucci G., and Cobelli C. Models of subcutaneous insulin kinetics a critical review. Comput. Methods Programs Biomed. 62 (2000) 249-257
67. Oliva A., Farina J., and Llabres M. Development of two high-performance liquid chromatographic methods for the analysis and characterization of insulin and its degradation products in pharmaceutical preparations. J. Chrom. B 749 (2000) 25-34
68. Olsson P.-O., Arnqvist H., and von Schenck H. Miscibility of human semisynthetic regular and lente insulin and human biosynthetic regular and NPH insulin. Diabetes Care 10 (1987) 473-477
69. Pang Y., Sakagami M., and Byron P.R. Insulin self-association: effects on lung disposition kinetics in the airways of the isolated perfused rat lung (IPRL). Pharm. Res. 24 (2007) 1636-1644
70. Pekar A.H., and Frank B.H. Conformation of proinsulin. Comparison of insulin and proinsulin self-association at neutral pH. Biochemistry 11 (1972) 4013-4016
71. Ploughmann S., Hejlesen O.K., and Cavan D.A. Implementation of a New Insulin Model Covering Both Injection and Pump Delivery in Diasnet. Proceedings of the 25th Annual International Conference of the IEEE EMBS (2003) 1264-1267
72. Pocker Y., and Biswas S.B. Self-association of insulin and the role of hydrophobic bonding: a thermodynamic model of insulin dimerization. Biochemistry 20 (1981) 4354-4361
73. Puckett W.R., and Lightfoot E.N. A model for multiple subcutaneous insulin injections developed from individual diabetic patient data. Am. J. Physiol. Endocrinol. Metab. 269 (1995) E1115-E1124
74. Rahuel-Clermont S., French C., Kaarsholm N., and Dunn M.F. Mechanisms of stabilization of the insulin hexamer through allosteric ligand interactions. Biochemistry 36 (1997) 5837-5845
75. Ribel U., Jørgensen K., Brange J., and Henriksen U. The pig as a model for subcutaneous insulin absorption in man. In: Serrano-Rios M., and Lefèbvre P. (Eds). Diabetes 1985 (1986), Elsevier Science Publishers B.V. (Biomedical Division), Amsterdam 891-896
76. Shimoda S., Nishida K., Sakakida M., Konno Y., Ichinose K., Uehara M., Nowak T., and Shichiri M. Closed-loop subcutaneous insulin infusion algorithm with a short-acting insulin analog for long-term clinical application of a wearable artificial endocrine pancreas. Frontiers Med. Biol. Eng. 8 (1997) 197-211
77. Simkin R., Cole S., Ozawa H., Magdoff-Fairchild B., Eggena P., Rudko A., and Low B. Precipitation and crystallization of insulin in the presence of lysozyme and salmine. Biochim. Biophys. Acta 200 (1970) 385-394
78. Storm M.C., and Dunn M.F. The Glu(B13) carboxylates of the insulin hexamer form a cage for cadmium and calcium ions. Biochemistry 24 (1985) 1749-1756
79. Strazza S., Hunter R., Walker E., and Darnall D.W. The thermodynamics of bovine and porcine insulin and proinsulin association determined by concentration difference spectroscopy. Arch. Biochem. Biophys. 238 (1985) 30-42
80. Tarín C., Teufel E., Picó J., Bondia J., and Pfleiderer H.-J. Comprehensive pharmacokinetic model of insulin glargine and other insulin formulations. IEEE Transact. Biomed. Eng. 52 (2005) 1994-2005
81. Trajanoski Z., Wach P., Kotanko P., Ott A., and Skraba F. Pharmacokinetic model for the absorption of subcutaneously injected soluble insulin and monomeric insulin analogues. Biomed. Tecknik 38 (1993) 224-231
82. Valensi P. Changes in capillary permeability in diabetic patients. Clin. Hemorheol. Microcirc. 17 (1997) 389-394
83. Vora J.P., Burch A., Peters J.R., and Owens D.R. Relationship between absorption of radiolabeled soluble insulin, subcutaneous blood flow, and anthropometry. Diabetes Care 15 (1992) 1484-1493
84. Wach P., Trajanoski Z., Kotanko P., and Skrabal F. Numerical approximation of mathematical model for absorption of subcutaneously injected insulin. Med. Bio. Eng. Comput. 33 (1995) 18-23
85. Williams G., Pickup J., Clark A., Bowcock S., Cooke E., and Keen H. Changes in blood flow close to subcutaneous insulin injection sites in stable and brittle diabetics. Diabetes 32 (1983) 466-473
86. World Health Organization, 2006. Diabetes. Fact sheet No. 312. http://www.who.int/mediacentre/factsheets/fs312/en/print.html. Accessed 27-5-2008.
87. Yki-Järvinen H., and Utriainen T. Insulin-induced vasodilatation: physiology or pharmacology. Diabetologia 41 (1998) 369-379